Have diagnosis of prostate cancer and have received treatment with GnRH agonist or antagonist therapy for at least 1 month prior to enrollment.
Willing and able to complete survey questionnaires in English without assistance through the duration of the study. This stipulation is in place because not all of the proposed quality of life or cognitive tests are available or validated in other languages.
Age = 18 years.
Ability to understand and the willingness to sign a written informed consent document written in English that is approved by an institutional review board.
Have either newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) or castration-resistant metastatic prostate cancer (mCRPC) and eligible to undergo treatment with abiraterone acetate (mHSPC or mCRPC) or enzalutamide (mCRPC)
Patients may have received the following prior AR directed therapy prior to enrollment: bicalutamide, ketoconazole. Prior to enrollment, patients may have received treatment with abiraterone acetate or enzalutamide for no more than 14 days before completing baseline studies.
Patients may have received chemotherapy for hormone-sensitive metastatic prostate cancer only, but it must not have lasted for more than 6 months. At least 12 months must have elapsed since completion of chemotherapy.
Patients may have received prior definitive radiation therapy or surgery. At least 60 days must have elapsed since completion of definitive radiation therapy or surgery and patient must have only grade 2 or less adverse effects at the time of registration. Enrollment during palliative radiation of = 10 days, or radiation of = 10 days during the duration of the study is allowed.
Patients must be able to take oral medication.

NCT03016741_inc_T1
Condition
prostate cancer
NCT03016741_inc_T2
Drug
GnRH agonist
NCT03016741_inc_T3
Drug
GnRH antagonist
NCT03016741_inc_T4
Multiplier
for at least 1 month
NCT03016741_inc_T5
Temporal
prior to enrollment
NCT03016741_inc_T6
Procedure
treatment
NCT03016741_inc_T7
Scope
GnRH agonist or antagonist
NCT03016741_inc_T9
Person
Age
NCT03016741_inc_T10
Value
= 18 years
NCT03016741_inc_T12
Qualifier
metastatic
NCT03016741_inc_T13
Qualifier
hormone sensitive
NCT03016741_inc_T14
Condition
prostate cancer
NCT03016741_inc_T15
Condition
mHSPC
NCT03016741_inc_T16
Scope
metastatic hormone sensitive prostate cancer
NCT03016741_inc_T17
Qualifier
castration-resistant
NCT03016741_inc_T18
Qualifier
metastatic
NCT03016741_inc_T19
Condition
prostate cancer
NCT03016741_inc_T20
Condition
mCRPC
NCT03016741_inc_T21
Scope
castration-resistant metastatic prostate cancer
NCT03016741_inc_T22
Drug
abiraterone acetate
NCT03016741_inc_T23
Procedure
treatment
NCT03016741_inc_T24
Condition
mHSPC
NCT03016741_inc_T25
Condition
mCRPC
NCT03016741_inc_T26
Drug
enzalutamide
NCT03016741_inc_T27
Condition
mCRPC
NCT03016741_inc_T28
Scope
abiraterone acetate (mHSPC or mCRPC) or enzalutamide (mCRPC
NCT03016741_inc_T29
Scope
enzalutamide (mCRPC)
NCT03016741_inc_T30
Scope
abiraterone acetate (mHSPC or mCRPC)
NCT03016741_inc_T31
Scope
castration-resistant metastatic prostate cancer (mCRPC) and eligible to undergo treatment with abiraterone acetate (mHSPC or mCRPC) or enzalutamide (mCRPC)
NCT03016741_inc_T32
Procedure
chemotherapy
NCT03016741_inc_T33
Qualifier
hormone-sensitive
NCT03016741_inc_T34
Qualifier
metastatic
NCT03016741_inc_T35
Condition
prostate cancer
NCT03016741_inc_T36
Multiplier
lasted for more than 6 months
NCT03016741_inc_T37
Negation
not
NCT03016741_inc_T38
Temporal
At least 12 months must have elapsed since completion of chemotherapy
NCT03016741_inc_T39
Reference_point
completion of chemotherapy
NCT03016741_inc_T40
Procedure
chemotherapy
NCT03016741_inc_T41
Temporal
prior
NCT03016741_inc_T42
Qualifier
definitive
NCT03016741_inc_T43
Procedure
radiation therapy
NCT03016741_inc_T44
Procedure
surgery
NCT03016741_inc_T45
Scope
radiation therapy or surgery
NCT03016741_inc_T46
Temporal
At least 60 days must have elapsed since completion of definitive radiation therapy or surgery
NCT03016741_inc_T47
Procedure
radiation therapy
NCT03016741_inc_T48
Procedure
surgery
NCT03016741_inc_T49
Qualifier
definitive
NCT03016741_inc_T50
Reference_point
completion of definitive radiation therapy or surgery
NCT03016741_inc_T51
Qualifier
grade 2 or less
NCT03016741_inc_T52
Condition
adverse effects
NCT03016741_inc_T53
Temporal
at the time of registration